Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in patients with cardiovascular disease (FOURIER)
NCT01764633Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2013
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 49
01
Overview
A Phase 3 trial of evolocumab in atherosclerotic cardiovascular disease (ASCVD), sponsored by Amgen. Started Feb 2013; status: completed.
02
Drugs
evolocumab
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT01764633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01764633.